ArticleJournal of cheminformatics2025
HERGAI: an artificial intelligence tool for structure-based prediction of hERG inhibitors.
Article in Journal of cheminformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Modeling hERG Channel Liability: From Structural Insight to Highly Accurate Qualitative and Quantitative Models.Journal of chemical information and modeling · 2026Article
- Toxicological investigation of mycotoxin contaminants and antibiotic residues associated with the poultry industry and their impact on human health.RSC advances · 2026Article
- Artificial intelligence in drug discovery: from algorithmic foundations to clinical translation.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The human Ether-à-go-go-Related Gene (hERG) potassium channel is crucial for repolarizing the cardiac action potential and regulating the heartbeat. Molecules that inhibit this protein can cause acquired long QT syndrome, increasing the risk of arrhythmias and sudden fatal cardiac arrests. Detecting compounds with potential hERG inhibitory activity is therefore essential to mitigate cardiotoxicity risks. In this article, we present a new hERG data set of unprecedented size, comprising nearly 300,000 molecules reported in PubChem and ChEMBL, approximately 2000 of which were confirmed hERG blockers identified through in vitro assays. Multiple structure-based artificial intelligence (AI) binary classifiers for predicting hERG inhibitors were developed, employing, as descriptors, protein-ligand extended connectivity (PLEC) fingerprints fed into random forest, extreme gradient boosting, and deep neural network (DNN) algorithms. Our best-performing model, a stacking ensemble classifier with a DNN meta-learner, achieved state-of-the-art classification performance, accurately identifying 86% of molecules having half-maximal inhibitory concentrations (IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.